A detailed history of Black Rock Inc. transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Black Rock Inc. holds 871,793 shares of IMCR stock, worth $28.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
871,793
Previous 867,357 0.51%
Holding current value
$28.4 Million
Previous $56.4 Million 47.59%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$33.78 - $63.75 $149,848 - $282,795
4,436 Added 0.51%
871,793 $29.5 Million
Q1 2024

May 10, 2024

BUY
$60.14 - $75.36 $5.31 Million - $6.66 Million
88,326 Added 11.34%
867,357 $56.4 Million
Q4 2023

Feb 13, 2024

BUY
$42.85 - $69.5 $822,634 - $1.33 Million
19,198 Added 2.53%
779,031 $53.2 Million
Q3 2023

Nov 13, 2023

SELL
$49.5 - $66.6 $1.6 Million - $2.15 Million
-32,251 Reduced 4.07%
759,833 $39.4 Million
Q2 2023

Aug 11, 2023

BUY
$48.54 - $61.64 $687,229 - $872,699
14,158 Added 1.82%
792,084 $47.5 Million
Q1 2023

May 12, 2023

SELL
$46.12 - $65.71 $510,502 - $727,343
-11,069 Reduced 1.4%
777,926 $38.5 Million
Q4 2022

Feb 13, 2023

BUY
$45.51 - $65.08 $13.2 Million - $18.8 Million
289,563 Added 57.98%
788,995 $45 Million
Q3 2022

Nov 14, 2022

BUY
$37.34 - $57.44 $121,355 - $186,680
3,250 Added 0.66%
499,432 $23.4 Million
Q4 2021

Feb 10, 2022

SELL
$27.58 - $40.0 $9.14 Million - $13.3 Million
-331,422 Reduced 40.05%
496,182 $17 Million
Q3 2021

Nov 09, 2021

SELL
$27.98 - $40.0 $7.06 Million - $10.1 Million
-252,322 Reduced 23.36%
827,604 $30.7 Million
Q2 2021

Aug 11, 2021

BUY
$32.22 - $41.5 $34.8 Million - $44.8 Million
1,079,926 New
1,079,926 $42.2 Million

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.43B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.